3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
6
Neoplasms
4
Colorectal Neoplasms
4
Stomach Neoplasms
3
Glioma
2
Weight Loss
1
Triple Negative Breast Neoplasms
1
Solid Tumor Cancer
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Refractory Solid Tumors
1
Recurrence
1
Rectal Neoplasms
1
Pseudomyxoma Peritonei
1
Peritoneal Neoplasms
1
Pancreatic cancer, adult
1
Pancreatic Diseases
1
Ovarian Neoplasms
1
Osteosarcoma
1
Oligodendroglioma
1
Neuroblastoma
1
Neoplasms, Cystic, Mucinous, and Serous
1
Neoplasm Metastasis
1
Metastatic Pancreatic Adenocarcinoma
1
Mesothelioma
1
Malignant Solid Neoplasm
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Interventions
remune
1
olanzapine-fluoxetine combination
1
irinotecan sucrosofate
1
bermekimab
1
Surveys and Questionnaires
1
Ritonavir
1
Quality of Life
1
Olanzapine
1
Metformin
1
Fluoxetine
1
Fluorouracil
1
Exercise
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Weight Loss
×
irinotecan sucrosofate
×
Clear all
NCT03207724
2020-12-30
OnFX
Cedars-Sinai Medical Center
Phase 1
Completed
16 enrolled